Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Supreme Court Strengthens Generic Liability Shield; FDA Reg Change Could Create Opening

This article was originally published in The Pink Sheet Daily

Executive Summary

The high court rules 5-4 that generic drug makers cannot be sued for alleged design defects based on the adequacy of a drug’s label warnings; FDA continues to discuss revising its regulations to allow generic companies to change their labeling.

Advertisement

Related Content

Brand-Name Drug Makers' Duty To Warn Extends After Product Sale To Another Company
Brand-Name Drug Makers' Duty To Warn Extends After Product Sale To Another Company
FDA's Biosimilar Labeling Stance Spurs Preemption Questions
Preemption Preference: Supreme Court Seems Wary Of Having Jurors Override FDA Safety Decisions
FDA May Drop Generic Liability Shield, Allow ANDA Manufacturers To Change Labels
Manufacturing Patents In Peril After Court Extends Hatch-Waxman “Safe Harbor”

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS075871

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel